公开(公告)号：US20190298819A1

公开(公告)日：2019-10-03

申请号：US16315986

申请日：2017-07-07

Applicant: Hawaii Biotech Inc. ,  Infectious Disease Research Institute

Inventor： David E. Clements ,  Neal Van Hoeven

IPC: A61K39/12 ,  A61K39/39 ,  A61K9/127 ,  A61P31/14

Abstract: A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.

公开(公告)号：US20230312656A1

公开(公告)日：2023-10-05

申请号：US18024538

申请日：2021-09-01

Applicant: Hawaii Biotech, Inc.

Inventor： David E. Clements ,  James T. Senda ,  Jaime S. Horton

IPC: C07K14/005 ,  C12N15/85 ,  A61K39/39 ,  A61K39/215 ,  A61P31/14

CPC classification number: C07K14/005 ,  C12N15/85 ,  A61K39/39 ,  A61K39/215 ,  A61P31/14 ,  C12N2770/20022 ,  C12N2770/20034 ,  A61K2039/55572

Abstract: The present invention is directed to the expression and secretion recombinant SARS-CoV-2 spike protein subunits. Various subunits have been designed and expressed as secreted products into the culture medium of transformed insect cell lines. The design of subunits is focused on the production of products that provide the ability to induce focused immune responses without inducing immune enhancing responses. The expressed and purified products are suitable as vaccine candidates to protect against disease caused by SARS-CoV-2.

公开(公告)号：US11434261B2

公开(公告)日：2022-09-06

申请号：US16320983

申请日：2017-07-26

Applicant: Hawaii Biotech Inc.

Inventor： David E. Clements

IPC: C07K14/005 ,  A61P31/14 ,  A61K39/12 ,  A61K39/39 ,  C12N15/85 ,  A61K39/00

Abstract: The present invention is directed to the expression and secretion the Zika virus envelope protein. Elements of the pre-membrane and envelope sequence have been modified to enhance the expression of the envelope protein as a secreted product in the culture medium of transformed insect cell lines. The expressed and purified product is suitable as a vaccine antigen.

公开(公告)号：US20210332084A1

公开(公告)日：2021-10-28

申请号：US16320983

申请日：2017-07-26

Applicant: Hawaii Biotech Inc.

Inventor： David E. Clements

IPC: C07K14/005 ,  C12N15/85 ,  A61K39/12 ,  A61K39/39 ,  A61P31/14

Abstract: The present invention is directed to the expression and secretion the Zika virus envelope protein. Elements of the pre-membrane and envelope sequence have been modified to enhance the expression of the envelope protein as a secreted product in the culture medium of transformed insect cell lines. The expressed and purified product is suitable as a vaccine antigen.

公开(公告)号：US11135281B2

公开(公告)日：2021-10-05

申请号：US16315986

申请日：2017-07-07

Applicant: Hawaii Biotech Inc. ,  Infectious Disease Research Institute

Inventor： David E. Clements ,  Neal Van Hoeven

IPC: A61K39/12 ,  A61K31/14 ,  A61K9/127 ,  A61K39/39 ,  A61P31/14 ,  A61K36/00 ,  A61K36/73 ,  A61K39/00

Abstract: A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.